Consistent with the aforementioned findings, a study conducted by Wu et al. [47] identified a low pre-treatment serum ALB/CRP ratio as an independent predictor for worse OS and DFS in HCC patients treated with curative surgical resection, RFA, TACE, or systemic chemotherapy. The gene discussed is CRP; the disease is hepatocellular carcinoma.